PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(02): 143-148
DOI: 10.4103/wjnm.wjnm_38_18
Original Article

Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer

Autor*innen

  • Yaw Ampem Amoako

    1   Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana, West Africa

  • Emmanuel Nii Boye Hammond

    2   Department of Nuclear Medicine Service, Korle Bu Teaching Hospital, Accra, Ghana, West Africa
    3   Department of Ghana Atomic Energy Commission, Accra, Ghana, West Africa

  • Awo Assasie-Gyimah

    2   Department of Nuclear Medicine Service, Korle Bu Teaching Hospital, Accra, Ghana, West Africa

  • Dennis Odai Laryea

    4   Department of Non Communicable Disease Control Programme, Ghana Health Service Headquarters, Accra, Ghana, West Africa

  • Alfred Ankrah

    2   Department of Nuclear Medicine Service, Korle Bu Teaching Hospital, Accra, Ghana, West Africa
    5   Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa
    6   Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Netherland

  • George Amoah

    7   Department of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

We aimed to assess the relationship between bone scintigraphy findings and prostate-specific antigen (PSA) and Gleason score in a group of treatment naïve West Africans with prostate cancer. The age, PSA, and Gleason scores of 363 patients with prostate cancer were collected. Patients were risk stratified using the D'Amico criteria. Logistic regression was performed to assess the relationship between bone scan results and PSA and Gleason score. Receiver operating characteristics (ROC) analysis was used to determine the diagnostic reliability of the bone scan findings. Ninety of the 96 patients with metastases had high risk, and only 6 had low-to-intermediate risk disease (P = 0.0001). PSA (odds ratio [OR] 2.4 [95% confidence interval [CI] 1.5–3.8], P = 0.001) and GS (OR 2.2 [95% CI 1.5–3.1], P = 0.001) were independently predictive of the presence of metastases. ROC analysis revealed that PSA predicted the presence of metastases with an area under the curve of 0.72, and using a cut-off value of ≥20 predicted metastases with a sensitivity of 86.5% and specificity of 41.2%. A Gleason score of ≥7 had an 89.6% sensitivity and 34.8% specificity for bone metastases. Using a Gleason cutoff of ≥8, the sensitivity and specificity for predicting bone metastases were 54.2% and 71.5%, respectively. The area under the Gleason score ROC curve was 0.68. PSA and Gleason score are independent predictors of the presence of bone metastases in West Africans with prostate cancer.

Keywords

Bone scintigraphy - Ghana - Gleason score - prostate cancer - prostate-specific antigen

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 00. 00 2019

Angenommen: 00. 00 2019

Artikel online veröffentlicht:
22. April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-48.
  • 2 Calys-Tagoe BN, Yarney J, Kenu E, Amanhyia NA, Enchill E, Obeng I, et al. Profile of cancer patients' seen at Korle Bu teaching hospital in Ghana (a cancer registry review). BMC Res Notes 2014;7:577.
  • 3 Laryea DO, Awuah B, Amoako YA, Osei-Bonsu E, Dogbe J, Larsen-Reindorf R, et al. Cancer incidence in Ghana, 2012: Evidence from a population-based cancer registry. BMC Cancer 2014;14:362.
  • 4 Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 2016;34:1652-9.
  • 5 Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37.
  • 6 Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and68 Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:2114-21.
  • 7 Cook GJ, Azad G, Padhani AR. Bone imaging in prostate cancer: The evolving roles of nuclear medicine and radiology. Clin Transl Imaging 2016;4:439-47.
  • 8 Langsteger W, Rezaee A, Pirich C, Beheshti M.18 F-NaF-PET/CT and99m Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med 2016;46:491-501.
  • 9 Bouchelouche K, Choyke PL. Prostate-specific membrane antigen positron emission tomography in prostate cancer: A step toward personalized medicine. Curr Opin Oncol 2016;28:216-21.
  • 10 Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and radionuclide therapy in prostate cancer. Semin Nucl Med 2016;46:522-35.
  • 11 An H, Tao N, Li J, Guan Y, Wang W, Wang Y, et al. Detection of prostate cancer metastasis by whole body magnetic resonance imaging combined with bone scintigraphy and PSA levels. Cell Physiol Biochem 2016;40:1052-62.
  • 12 Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
  • 13 Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000;48:1443-6.
  • 14 Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: A summary of the literature. J Urol 2004;171:2122-7.
  • 15 Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S, et al. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of < =20 ng/ml and Gleason score of < =6 at the initial stage of diagnosis. Jpn J Clin Oncol 2011;41:1209-13.
  • 16 Al-Ghazo MA, Ghalayini IF, Al-Azab RS, Bani-Hani I, Barham A, Haddad Y, et al. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study. Int Braz J Urol 2010;36:685-91.
  • 17 D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
  • 18 Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016;43:1723-38.
  • 19 Donohoe KJ, Henkin RE, Royal HD, Brown ML, Collier BD, O'Mara RE, et al. Procedure guideline for bone scintigraphy: 1.0. Society of Nuclear Medicine. J Nucl Med 1996;37:1903-6.
  • 20 Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: An overview. Oncol Rev 2017;11:321.
  • 21 Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618-29.
  • 22 Ekeke O, Amusan O, Eke N. Management of prostate cancer in Port Harcourt, Nigeria: Changing patterns. J West Afr Coll Surg 2012;2:58-77.
  • 23 Yeboah ED, Hsing AW, Mante S, Mensah JE, Kyei MY, Yarney J, et al. Management of prostate cancer in Accra, Ghana. J West Afr Coll Surg 2016;6:31-65.
  • 24 Janane A, Jawad C, Hajji F, Ould T, Ghadouane M, Ameur A, et al. Bone scan findings in a North African Ethnic Group and relation to PSA level and gleason score of the biopsy. Actas Urol Esp 2011;35:534-9.
  • 25 Qureshi AM, Makhdomi K, Stones W. Prostate-specific antigen as a risk factor for skeletal metastasis in native ethnic African men with prostate cancer: A case-control study. World J Nucl Med 2017;16:26-32.
  • 26 Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer 2013;2013:560857.
  • 27 Khalid KE, Brair AI, Elhaj AM, Ali KE. Prostate-specific antigen level and risk of bone metastasis in Sudanese patients with prostate cancer. Saudi J Kidney Dis Transpl 2011;22:1041-3.